{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:16:51Z","timestamp":1769311011280,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"am","delay-in-days":303,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01GM094449"],"award-info":[{"award-number":["R01GM094449"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-18IBS-172"],"award-info":[{"award-number":["1-18IBS-172"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Heart Association Predoctoral Fellowship","award":["14PRE18310014"],"award-info":[{"award-number":["14PRE18310014"]}]},{"name":"American Heart Association Predoctoral Fellowship","award":["16PRE27250308"],"award-info":[{"award-number":["16PRE27250308"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30-EY014801"],"award-info":[{"award-number":["P30-EY014801"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"RPB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.exer.2019.01.009","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T18:19:43Z","timestamp":1546971583000},"page":"120-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Secretogranin III as a novel target for the therapy of choroidal neovascularization"],"prefix":"10.1016","volume":"181","author":[{"given":"Michelle E.","family":"LeBlanc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dachuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2019.01.009_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.01.009_bib2","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1167\/iovs.09-4144","article-title":"Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2\/PI3K\/Akt","volume":"51","author":"Byeon","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.01.009_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40942-017-0084-9","article-title":"Retinal and choroidal angiogenesis: a review of new targets","volume":"3","author":"Cabral","year":"2017","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.exer.2019.01.009_bib4","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1167\/iovs.09-4956","article-title":"A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap","volume":"51","author":"Cao","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.01.009_bib5","unstructured":"ClinicalTrialgov. GW824575 First Time in Human (ClinicalTrials.gov Identifier: NCT01551771), at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01551771?term=age-related+macular+degeneration+AND+CCR3&rank=1."},{"key":"10.1016\/j.exer.2019.01.009_bib6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.01.009_bib7","first-page":"533","article-title":"Current perspectives on ranibizumab","volume":"9","author":"Dedania","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2019.01.009_bib8","series-title":"Eylea Prescribing Information by U.S","author":"Drug_Information","year":"2011"},{"key":"10.1016\/j.exer.2019.01.009_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3928\/23258160-20170130-02","article-title":"An overview of the Fovista and rinucumab trials and the fate of anti-PDGF medications","volume":"48","author":"Dunn","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.exer.2019.01.009_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/OED.S38863","article-title":"Association of anti-VEGF injections with progression of geographic atrophy","volume":"8","author":"Enslow","year":"2016","journal-title":"Ophthalmol. Eye Dis."},{"key":"10.1016\/j.exer.2019.01.009_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.critrevonc.2015.01.012","article-title":"Bevacizumab: a dose review","volume":"94","author":"Falk","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.exer.2019.01.009_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 Years of comparison of age-related macular degeneration treatments trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.01.009_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00018-014-1750-9","article-title":"Chromogranin A: a paradoxical player in angiogenesis and vascular biology","volume":"72","author":"Helle","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.exer.2019.01.009_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1507\/endocrj.K10E-038","article-title":"Secretogranin III: a bridge between core hormone aggregates and the secretory granule membrane","volume":"57","author":"Hosaka","year":"2010","journal-title":"Endocr. J."},{"key":"10.1016\/j.exer.2019.01.009_bib15","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1091\/mbc.02-03-0040","article-title":"Identification of a chromogranin A domain that mediates binding to secretogranin III and targeting to secretory granules in pituitary cells and pancreatic beta-cells","volume":"13","author":"Hosaka","year":"2002","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.exer.2019.01.009_bib16","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1073\/pnas.261462598","article-title":"The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness","volume":"99","author":"Humbles","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.exer.2019.01.009_bib17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exer.2019.01.009_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/j.1460-2075.1990.tb08123.x","article-title":"Genetic ablation of a mouse gene expressed specifically in brain","volume":"9","author":"Kingsley","year":"1990","journal-title":"EMBO J."},{"key":"10.1016\/j.exer.2019.01.009_bib19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/01.CIR.0000112574.07422.C1","article-title":"The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo","volume":"109","author":"Kirchmair","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.exer.2019.01.009_bib20","doi-asserted-by":"crossref","first-page":"e0127904","DOI":"10.1371\/journal.pone.0127904","article-title":"Hepatoma-derived growth factor-related protein-3 is a novel angiogenic factor","volume":"10","author":"LeBlanc","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2019.01.009_bib21","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1084\/jem.20161802","article-title":"Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy","volume":"214","author":"LeBlanc","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.exer.2019.01.009_bib22","first-page":"374","article-title":"The regulatory role of hepatoma-derived growth factor as an angiogenic factor in the eye","volume":"22","author":"LeBlanc","year":"2016","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2019.01.009_bib23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.drudis.2018.01.013","article-title":"Ligandomics: a paradigm shift in biological drug discovery","volume":"23","author":"Li","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.exer.2019.01.009_bib24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00018-017-2635-5","article-title":"Secretogranin III: a diabetic retinopathy-selective angiogenic factor","volume":"75","author":"Li","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.exer.2019.01.009_bib25","doi-asserted-by":"crossref","first-page":"e17106","DOI":"10.1371\/journal.pone.0017106","article-title":"CCR3 and choroidal neovascularization","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2019.01.009_bib26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1210\/en.2017-00636","article-title":"Impaired processing of prohormones in secretogranin III-null mice causes maladaptation to an inadequate diet and stress","volume":"159","author":"Maeda","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.exer.2019.01.009_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tem.2013.08.002","article-title":"Unlocking the biology of RAGE in diabetic microvascular complications","volume":"25","author":"Manigrasso","year":"2014","journal-title":"Trends Endocrinol. Metabol.: TEM (Trends Endocrinol. Metab.)"},{"key":"10.1016\/j.exer.2019.01.009_bib28","series-title":"Janeway's Immunobiology","author":"Murphy","year":"2017"},{"key":"10.1016\/j.exer.2019.01.009_bib29","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.ajpath.2015.04.029","article-title":"Novel CCR3 antagonists are effective mono- and combination inhibitors of choroidal neovascular growth and vascular permeability","volume":"185","author":"Nagai","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exer.2019.01.009_bib30","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1523\/JNEUROSCI.10-09-03135.1990","article-title":"1B1075: a brain- and pituitary-specific mRNA that encodes a novel chromogranin\/secretogranin-like component of intracellular vesicles","volume":"10","author":"Ottiger","year":"1990","journal-title":"J. Neurosci."},{"key":"10.1016\/j.exer.2019.01.009_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000363422","article-title":"Switch from intravitreal ranibizumab to bevacizumab for the treatment of neovascular age-related macular degeneration: clinical comparison","volume":"232","author":"Pinheiro-Costa","year":"2014","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.exer.2019.01.009_bib32","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1167\/iovs.14-15067","article-title":"Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation","volume":"55","author":"Poor","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.01.009_bib33","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.01.009_bib34","doi-asserted-by":"crossref","first-page":"11036","DOI":"10.1523\/JNEUROSCI.23-35-11036.2003","article-title":"Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons","volume":"23","author":"Rosenstein","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.exer.2019.01.009_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/002215540305100211","article-title":"Immunocytochemical localization of secretogranin III in the anterior lobe of male rat pituitary glands","volume":"51","author":"Sakai","year":"2003","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.exer.2019.01.009_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1679\/aohc.67.57","article-title":"Immunocytochemical localization of secretogranin III in the endocrine pancreas of male rats","volume":"67","author":"Sakai","year":"2004","journal-title":"Arch. Histol. Cytol."},{"key":"10.1016\/j.exer.2019.01.009_bib37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","article-title":"Advances in antibody-drug conjugates: a new era of targeted cancer therapy","volume":"22","author":"Sau","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.exer.2019.01.009_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature08151","article-title":"CCR3 is a target for age-related macular degeneration diagnosis and therapy","volume":"460","author":"Takeda","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.exer.2019.01.009_bib39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/eye.2001.147","article-title":"Neovascular age-related macular degeneration: present and future treatment options","volume":"15","author":"Votruba","year":"2001","journal-title":"Eye"},{"key":"10.1016\/j.exer.2019.01.009_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10456-017-9557-6","article-title":"Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease","volume":"20","author":"Wang","year":"2017","journal-title":"Angiogenesis"},{"key":"10.1016\/j.exer.2019.01.009_bib41","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483518303762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483518303762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:59:39Z","timestamp":1757998779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483518303762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":41,"alternative-id":["S0014483518303762"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2019.01.009","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secretogranin III as a novel target for the therapy of choroidal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2019.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}